Gemifloxacina (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Gemifloxacina" in Italian language version.

refsWebsite

Global rank Italian rank

10nih.gov

4^th place

9^th place

6doi.org

2^nd place

7^th place

4oadoi.org

799^th place

22^nd place

2archive.org

6^th place

8^th place

1asm.org

3,555^th place

2,382^nd place

1wiley.com

222^nd place

243^rd place

archive.org

Allen A, Bygate E, Vousden M, Oliver S, Johnson M, Ward C, Cheon A, Choo YS, Kim I, Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers, in Antimicrob. Agents Chemother., vol. 45, n. 2, 2001, pp. 540–5, DOI:10.1128/AAC.45.2.540-545.2001, PMC 90324, PMID 11158752. URL consultato il 12 gennaio 2015.
Allen A, Bygate E, Clark D, Lewis A, Pay V, The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers, in Int. J. Antimicrob. Agents, vol. 16, n. 1, 2000, pp. 45–50, DOI:10.1016/S0924-8579(00)00181-3, PMID 11185412. URL consultato il 12 gennaio 2015.

asm.org

aac.asm.org

Allen A, Bygate E, Oliver S, Johnson M, Ward C, Cheon AJ, Choo YS, Kim IC, Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers, in Antimicrob. Agents Chemother., vol. 44, n. 6, 2000, pp. 1604–8, PMC 89920, PMID 10817716. URL consultato il 12 gennaio 2015.

doi.org

dx.doi.org

Allen A, Bygate E, Vousden M, Oliver S, Johnson M, Ward C, Cheon A, Choo YS, Kim I, Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers, in Antimicrob. Agents Chemother., vol. 45, n. 2, 2001, pp. 540–5, DOI:10.1128/AAC.45.2.540-545.2001, PMC 90324, PMID 11158752. URL consultato il 12 gennaio 2015.
Allen A, Bygate E, Clark D, Lewis A, Pay V, The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers, in Int. J. Antimicrob. Agents, vol. 16, n. 1, 2000, pp. 45–50, DOI:10.1016/S0924-8579(00)00181-3, PMID 11185412. URL consultato il 12 gennaio 2015.
File TM, Mandell LA, Tillotson G, Kostov K, Georgiev O, Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study, in J. Antimicrob. Chemother., vol. 60, n. 1, 2007, pp. 112–20, DOI:10.1093/jac/dkm119, PMID 17537866. URL consultato il 12 gennaio 2015.
Ball P, Mandell L, Patou G, Dankner W, Tillotson G, A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context, in Int. J. Antimicrob. Agents, vol. 23, n. 5, 2004, pp. 421–9, DOI:10.1016/j.ijantimicag.2004.02.014, PMID 15120718. URL consultato il 12 gennaio 2015.
Stahlmann R, Lode H, Safety considerations of fluoroquinolones in the elderly: an update, in Drugs Aging, vol. 27, n. 3, 2010, pp. 193–209, DOI:10.2165/11531490-000000000-00000, PMID 20210367. URL consultato il 12 gennaio 2015.
Hooper DC, Wolfson JS, Fluoroquinolone antimicrobial agents, in N. Engl. J. Med., vol. 324, n. 6, 1991, pp. 384–94, DOI:10.1056/NEJM199102073240606, PMID 1987461. URL consultato il 12 gennaio 2015.

nih.gov

ncbi.nlm.nih.gov

Allen A, Bygate E, Oliver S, Johnson M, Ward C, Cheon AJ, Choo YS, Kim IC, Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers, in Antimicrob. Agents Chemother., vol. 44, n. 6, 2000, pp. 1604–8, PMC 89920, PMID 10817716. URL consultato il 12 gennaio 2015.
Allen A, Bygate E, Vousden M, Oliver S, Johnson M, Ward C, Cheon A, Choo YS, Kim I, Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers, in Antimicrob. Agents Chemother., vol. 45, n. 2, 2001, pp. 540–5, DOI:10.1128/AAC.45.2.540-545.2001, PMC 90324, PMID 11158752. URL consultato il 12 gennaio 2015.
Allen A, Bygate E, Clark D, Lewis A, Pay V, The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers, in Int. J. Antimicrob. Agents, vol. 16, n. 1, 2000, pp. 45–50, DOI:10.1016/S0924-8579(00)00181-3, PMID 11185412. URL consultato il 12 gennaio 2015.
Léophonte P, File T, Feldman C, Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin, in Respir Med, vol. 98, n. 8, 2004, pp. 708–20, PMID 15303634.
Sethi S, Fogarty C, Fulambarker A, A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis, in Respir Med, vol. 98, n. 8, 2004, pp. 697–707, PMID 15303633.
File TM, Mandell LA, Tillotson G, Kostov K, Georgiev O, Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study, in J. Antimicrob. Chemother., vol. 60, n. 1, 2007, pp. 112–20, DOI:10.1093/jac/dkm119, PMID 17537866. URL consultato il 12 gennaio 2015.
Ball P, Mandell L, Patou G, Dankner W, Tillotson G, A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context, in Int. J. Antimicrob. Agents, vol. 23, n. 5, 2004, pp. 421–9, DOI:10.1016/j.ijantimicag.2004.02.014, PMID 15120718. URL consultato il 12 gennaio 2015.
Bhavnani SM, Andes DR, Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety, in Pharmacotherapy, vol. 25, n. 5, 2005, pp. 717–40, PMID 15899734. URL consultato il 12 gennaio 2015.
Stahlmann R, Lode H, Safety considerations of fluoroquinolones in the elderly: an update, in Drugs Aging, vol. 27, n. 3, 2010, pp. 193–209, DOI:10.2165/11531490-000000000-00000, PMID 20210367. URL consultato il 12 gennaio 2015.
Hooper DC, Wolfson JS, Fluoroquinolone antimicrobial agents, in N. Engl. J. Med., vol. 324, n. 6, 1991, pp. 384–94, DOI:10.1056/NEJM199102073240606, PMID 1987461. URL consultato il 12 gennaio 2015.

oadoi.org

File TM, Mandell LA, Tillotson G, Kostov K, Georgiev O, Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study, in J. Antimicrob. Chemother., vol. 60, n. 1, 2007, pp. 112–20, DOI:10.1093/jac/dkm119, PMID 17537866. URL consultato il 12 gennaio 2015.
Ball P, Mandell L, Patou G, Dankner W, Tillotson G, A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context, in Int. J. Antimicrob. Agents, vol. 23, n. 5, 2004, pp. 421–9, DOI:10.1016/j.ijantimicag.2004.02.014, PMID 15120718. URL consultato il 12 gennaio 2015.
Stahlmann R, Lode H, Safety considerations of fluoroquinolones in the elderly: an update, in Drugs Aging, vol. 27, n. 3, 2010, pp. 193–209, DOI:10.2165/11531490-000000000-00000, PMID 20210367. URL consultato il 12 gennaio 2015.
Hooper DC, Wolfson JS, Fluoroquinolone antimicrobial agents, in N. Engl. J. Med., vol. 324, n. 6, 1991, pp. 384–94, DOI:10.1056/NEJM199102073240606, PMID 1987461. URL consultato il 12 gennaio 2015.

wiley.com

onlinelibrary.wiley.com

Bhavnani SM, Andes DR, Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety, in Pharmacotherapy, vol. 25, n. 5, 2005, pp. 717–40, PMID 15899734. URL consultato il 12 gennaio 2015.